MedTrace Logo

Thromboprophylaxis for Patients in ICU With COVID-19

NCT04623177 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 822

Last updated 2022-03-31

No results posted yet for this study

Summary

The respiratory distress that goes with COVID-19 infection has been related to a procoagulant state, with thrombosis at both venous and arterial levels, that determines hypoxia and tissue dysfunction at several organs. The main sign of this thrombotic activity seems to be the D-Dimers, that have been proposed to identify patients with poor prognosis at an early stage.

Knowledge on how to prevent or even treat this procoagulant state is scarce. COVID-19 patients may be out of general thromboprophylaxis recommendations, and recent studies suggest a better prognosis in severe COVID-19 patients receiving anticoagulant therapy with low molecular weight heparin (LMWH). However, the LMWH efficacy and safety, mainly in patients admitted to an Intensive Care Unit, remains to be validated.

Conditions

Sponsors & Collaborators

  • Hospital Universitario Doctor Peset

    collaborator OTHER

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Hospital Universitario La Paz

    collaborator OTHER

  • Hospital Universitario La Fe

    collaborator OTHER

  • Hospital de Sant Joan Despí Moisès Broggi

    collaborator OTHER

  • University of Navarrra Hospital (Clinica Universitaria)

    collaborator OTHER

  • Hospital de Cruces

    collaborator OTHER

  • Instituto de Investigacion Sanitaria La Fe

    lead OTHER

Principal Investigators

  • Raquel Ferrandis, MD · Hospital Universitario La Fe

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-09-30
Completion
2020-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04623177 on ClinicalTrials.gov